UnitedHealth Q2 2026: Net income +58.7% to $5.67B as operating income surges 55%; revenue flat at +0.4%

The company completed a strategic review in Q4 2025 and executed portfolio divestitures and restructuring actions. Year-to-date 2026, these actions produced a net gain of $191 million (despite a $39 million loss in Q2 2026 alone), primarily from sales of businesses held for sale at year-end 2025. The review focused on scaling core operations, particularly value-based care at Optum Health. Segment impacts included gains at Optum Insight ($524M) and Optum Rx ($8M), partially offset by a net loss at Optum Health ($341M).

The company voluntarily pledged to rebate all 2026 profits on individual exchange products to customers. This is a new disclosure not present in the prior-year filing. The pledge directly reduces revenue and profitability in the individual exchange segment while policymakers work on affordability solutions. Management frames this as a temporary measure pending regulatory clarity.

The company made a $400 million contribution to the United Health Foundation in the first half of 2026, funded by cash proceeds from an Optum Insight business disposition. This contribution was recorded within operating costs and reduced year-to-date operating income. The contribution reflects deployment of divestiture proceeds to the company's charitable foundation.

The company entered into a $3.0 billion acquisition agreement in Q1 2026 and closed the transaction on July 2, 2026 (post-quarter). The purchase price was structured as $1.5 billion cash at close and $1.5 billion deferred within one year. The target is described only as "a company in the health care sector." This represents a material capital deployment commitment.

Operating income increased 55% year-over-year to $8.0 billion (from $5.2 billion in Q2 2025). The prior-year period had been depressed by elevated medical cost trends that exceeded pricing assumptions. The current period benefited from favorable prior-period reserve development, affordability and medical cost management initiatives, and pricing actions, partially offset by continued elevated medical cost trends (though now better-managed). Operating margin expanded 2.5 percentage points to 7.1%.

Total UnitedHealthcare membership contracted by 1.6 million people year-over-year (48.5M in Q2 2026 vs. 50.1M in Q2 2025), reversing the prior year's 1.0 million net growth. The decline was driven by benefit design and pricing actions in Medicare Advantage (down 785k), reduced Medicaid eligibility and exit from one state (down 710k), and risk-based commercial contraction (down 785k), partially offset by fee-based commercial growth (+735k). This reflects the company's strategic response to funding pressures and elevated medical costs.

The medical care ratio (MCR) improved 2.7 percentage points year-over-year to 86.7% (from 89.4% in Q2 2025). The improvement was driven by favorable prior-period reserve development, affordability and medical cost management initiatives, and pricing trends, partially offset by medical cost trends that remain above historical levels (including higher provider reimbursement under the No Surprises Act and increased service/coding intensity in commercial). The prior-year period had seen MCR deterioration of 4.3 points due to medical costs significantly exceeding pricing assumptions.

Operating cash flow increased $7.3 billion (58%) year-over-year to $20.0 billion in the first half of 2026. The increase was driven by increased earnings, timing of government payments, other favorable working capital dynamics, and legislative changes from the Inflation Reduction Act impacting pharmacy rebates. This represents a significant improvement in cash generation.

Share repurchases declined to 10.5 million shares at an average price of $344.08 in H1 2026, compared to 12.1 million shares at $454.82 in H1 2025. Total cash spent on repurchases was $1.6 billion in 2026 versus $5.5 billion in 2025 (a $3.9 billion decrease). The lower average price reflects the market's valuation of the company during the repurchase period. Remaining authorization stood at 10.6 million shares as of June 30, 2026 (down from 21.0 million a year earlier).

The company shifted from net debt issuance of $1.6 billion in H1 2025 to net debt repayment of $4.8 billion in H1 2026, a $6.4 billion swing. This reflects deleveraging funded by strong operating cash flow ($20.0B) and divestiture proceeds ($1.1B). The company is reducing its debt footprint while maintaining capital allocation flexibility.

Optum Health's operating margin improved 3.4 percentage points year-over-year to 5.1% in Q2 2026 (from 1.7% in Q2 2025). The prior-year period had seen margin compression of 4.6 points (to 2.5% from 7.1% in Q2 2024) due to Medicare funding reductions, elevated medical cost trends, and member profile changes. The current-period improvement was driven by cost management, increased favorable reserve development, and the net decrease in loss contract reserves, partially offset by continued elevated medical cost trends, portfolio divestiture impacts, and growth investments.

Optum Rx script volume declined 6.5% year-over-year to 387 million scripts in Q2 2026 (from 414 million in Q2 2025). The decline was driven by reduced script volume resulting from the contraction in people served at UnitedHealthcare, partially offset by growth in retail and specialty pharmacy. The prior-year period had seen 3.8% script growth (to 414M from 399M) driven by new clients and existing-client growth.

The company's characterization of Medicare Advantage rate adequacy shifted slightly. The baseline described the 2026 Final Notice as "beginning to approach" the industry forward medical cost trend. The current filing describes the 2027 Final Notice as having "moved towards" the trend but still remaining "below" it. Both filings emphasize multi-year compounding rate shortfalls, but the current language suggests the 2027 rate improvement was incremental rather than fully closing the gap.

The company's Medicaid rate-adequacy language shifted from attributing the mismatch to the "redetermination process" (baseline) to a more general "timing mismatch" (current). The current filing no longer references the redetermination process as the driver, suggesting that the acuity/rate mismatch has persisted beyond the redetermination period and is now a structural issue. The core message — that rates remain insufficient and margins face downward pressure — is unchanged.

The Company disclosed a new IRS dispute over intercompany transfer pricing for 2017-2020, with the IRS seeking to significantly increase taxable income. The Company intends to contest the adjustments and believes its reserves for uncertain tax positions are adequate. This is a new disclosure not present in the prior period.

The Company moved Optum Financial (including Optum Bank) from Optum Health to Optum Insight effective January 1, 2026. This is a structural change in segment reporting, with prior periods recast for comparability. The four reportable segments remain the same.

The Company disclosed a new $3.3 billion receivables financing facility and provided details on receivables sold and collected during the first half of 2026. This is a new liquidity/working-capital management tool not disclosed in the prior period.

The Company disclosed portfolio divestitures and restructuring actions initiated in Q4 2025, resulting in a net gain of $191 million year-to-date 2026 (including gains at Optum Insight and Optum Rx, partially offset by losses at Optum Health). The Company also recorded a $400 million contribution to the United Health Foundation funded by proceeds from an Optum Insight disposition.

The Company disclosed a new $3.0 billion acquisition in the health care sector, completed on July 2, 2026 (after the quarter-end), with $1.5 billion paid in cash and $1.5 billion payable within one year. This is a new capital deployment not present in the prior period.

The Company raised its annual dividend rate from $8.84 to $9.28 per share in June 2026, a 5% increase. The prior period showed a raise from $8.40 to $8.84. This reflects continued dividend growth.

The Company disclosed a new $2.0 billion forward share repurchase contract executed in the first half of 2026, with 6.4 million shares purchased at an average price of $312.73. The contract settled on July 1, 2026. This is a new capital-return mechanism not present in the prior period.

The Company attributed $1.25 billion of favorable prior-year reserve development in 2026 to a favorable respiratory illness season, whereas the prior period had no individually significant factors. This is a material change in the driver of reserve releases.

The baseline disclosed a $3.0 billion debt issuance in June 2025 across four tranches. The current filing does not disclose a comparable issuance in 2026, though the cash-flow statement shows $2.5 billion of long-term debt repayments. This reflects a shift from net debt issuance to net debt reduction.

The current filing also provides more detail on the losses, including foreign currency translation effects.

The current filing discloses a single $3.0 billion acquisition (completed July 2, 2026) and does not reference the broader $4 billion pipeline. This suggests the prior pipeline either closed or was abandoned.